Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916737 | 0.79 | ALDH1A1 (0.53) | EDNRBEDNRAALDH1A1KDM4EMEN1 | |
| SCHEMBL28850201 | 0.79 | ALDH1A1 (0.53) | EDNRBEDNRAALDH1A1KDM4EMEN1 | |
| SCHEMBL4508527 | 0.77 | TSHR (0.40) | EDNRBEDNRAALDH1A1LMNACYP1A2 | |
| SCHEMBL14143066 | 0.77 | TSHR (0.40) | EDNRBEDNRAALDH1A1LMNACYP1A2 | |
| SCHEMBL27952654 | 0.77 | S100A4 (0.41) | EDNRBEDNRAALDH1A1KDM4ECYP3A4 | |
| SCHEMBL6660374 | 0.74 | EDNRA (0.42) | EDNRBEDNRAALDH1A1KMT2APOLB | |
| SCHEMBL15107233 | 0.74 | GLS (0.46) | EDNRBEDNRAALDH1A1MEN1KMT2A | |
| SCHEMBL5593897 | 0.73 | POLB (0.52) | EDNRBEDNRACYP1A2MEN1KMT2A | |
| SCHEMBL9367273 | 0.72 | ACHE (0.48) | ALDH1A1KDM4E | |
| SCHEMBL9372008 | 0.72 | ACHE (0.48) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276505-A1 | Acylhydrazine P2X7 antagonists and uses thereof | ABBOTT LABORATORIES | 2006-12-07 | — | — | US | disclosed |
| WO-2006110516-A1 | ACYLHYDRAZIDE P2X7 ANTAGONISTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276505-A1 | Acylhydrazine P2X7 antagonists and uses thereof | P2RX7, P2RX3, P2RX1 | EDNRB 397/4885EDNRA 326/4885ALDH1A1 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.